CTSN Embolic Protection Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 842 participants.

Also called NCT06027788

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 842 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06027788
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06027788. Randomized; single masking; primary purpose prevention. Start 2023-09-18 (actual); primary completion 2027-04-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CTSN Embolic Protection Trial
Acronym
EMPRO
Condition
Delirium
Condition
Heart Valve Disease
Intervention (Device)
CardioGard Embolic Protection Cannula
Intervention (Device)
Standard Aortic Cannula
Lead sponsor
Icahn School of Medicine at Mount Sinai (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct06027788
Content hash
5c3d26b4ef3d401065cfe035f77cc34cbaefb3fc5c5e499cc7fa1be9ee6ccb06